An ESR1 mutation is a change in the gene that produces the body’s primary estrogen receptor, a protein that sits inside cells and responds to estrogen. When this gene mutates in breast cancer cells, the receptor gets stuck in its “on” position and drives tumor growth even without estrogen present. This matters most for people with hormone receptor-positive breast cancer, where it can make standard hormone-blocking treatments ineffective.
What the ESR1 Gene Normally Does
The ESR1 gene provides instructions for building estrogen receptor alpha, the main protein through which estrogen exerts its effects throughout the body. When estrogen binds to this receptor, the protein moves into the cell’s nucleus, pairs up with a copy of itself, and switches on genes involved in growth, metabolism, sexual development, and reproduction. This receptor is active in breast tissue, the uterus, and bone, but also in many non-reproductive tissues including the brain and cardiovascular system.
In hormone receptor-positive (HR-positive) breast cancer, this normal signaling pathway is hijacked. Cancer cells rely on estrogen activating the receptor to fuel their growth. That’s why the most common treatments for HR-positive breast cancer work by either blocking estrogen production (aromatase inhibitors) or blocking the receptor itself (tamoxifen). For many patients, these therapies work well for years. But in some cases, the cancer finds a workaround: the ESR1 gene mutates.
How the Mutation Changes the Receptor
ESR1 mutations cluster in a specific hotspot within the part of the gene that encodes the receptor’s ligand-binding domain, the pocket where estrogen normally docks. Two point mutations account for roughly 70% of cases: one called Y537S and another called D538G. Both alter a single amino acid in the receptor’s structure, but the consequences are significant.
Normally, when estrogen enters the binding pocket, it causes a structural element called helix 12 to swing into an active position. This conformational shift is what allows the receptor to recruit helper proteins (coactivators) and turn on growth-promoting genes. In mutant receptors, helix 12 is permanently locked in that active position, mimicking the shape of an estrogen-bound receptor even when no estrogen is present. Molecular simulations and crystal structure studies confirm that both the Y537S and D538G mutations stabilize this agonist conformation. The result is a receptor that doesn’t need its signal to fire. It recruits coactivators on its own, activating gene transcription and driving cell division independently of estrogen.
This is why the mutations are classified as “gain of function.” The receptor hasn’t lost its ability to work. It has gained the ability to work all the time, without regulation.
Why It Causes Treatment Resistance
Because the mutant receptor no longer depends on estrogen, treatments designed to cut off the estrogen supply become far less effective. Aromatase inhibitors, which lower estrogen levels in the body, lose much of their power against these cells. Tamoxifen, which blocks the receptor’s binding pocket, and fulvestrant, which degrades the receptor protein, show only partial effectiveness against ESR1-mutant tumors.
The clinical data is striking. In one study, 75% of patients whose tumors carried ESR1 mutations showed primary endocrine resistance, compared to just 24% of patients without these mutations. Having an ESR1 mutation increased the odds of primary resistance more than eightfold, independent of tumor stage. Among patients with metastatic breast cancer and ESR1 mutations, 83% had a poor response to hormone therapy and a shorter duration of effective endocrine control. None of the patients with ESR1 mutations in one study showed a relapse pattern consistent with endocrine sensitivity.
There’s also evidence that different mutations respond differently to combination strategies. Patients with the D538G mutation saw improved progression-free survival when an additional targeted agent (everolimus) was added to their regimen, but patients with the Y537S mutation received no added benefit from the same combination.
Who Develops ESR1 Mutations
ESR1 mutations are rare in newly diagnosed breast cancers. They arise primarily under the selective pressure of endocrine therapy. When hormone-blocking treatment eliminates estrogen-dependent cancer cells, any cell that happens to carry an ESR1 mutation gains a survival advantage and can expand to become the dominant population. This is why these mutations are found overwhelmingly in the metastatic or recurrent setting, after patients have already received hormone therapy.
Prevalence estimates vary depending on the population studied and the sensitivity of the testing method. In one study of patients with ER-positive recurrent breast cancer who had completed five years of adjuvant hormone therapy, ESR1 mutations were detected in about 19% of cases. All of these patients had received an aromatase inhibitor at some point in their treatment and initially responded before their disease progressed.
How ESR1 Mutations Are Detected
The standard method for detecting ESR1 mutations is a liquid biopsy, a blood draw that analyzes fragments of tumor DNA circulating in the bloodstream (called circulating tumor DNA, or ctDNA). This approach has become the diagnostic standard rather than traditional tissue biopsy, in part because it’s less invasive and in part because it captures the genetic diversity of metastatic disease better than a single tissue sample can. Breast cancer metastases are often genetically varied across different sites in the body, and a blood test picks up DNA shed from all of them.
The two main laboratory techniques used are next-generation sequencing (NGS) and digital droplet PCR (ddPCR). NGS is more comprehensive, detecting ESR1 mutations alongside other clinically relevant gene changes in a single test, but it costs more. ddPCR is faster and less expensive, making it useful for targeted monitoring when the question is specifically about ESR1 status. Studies have shown that ctDNA testing can detect ESR1 mutations months before clinical disease progression becomes apparent on imaging. The FDA has approved a specific companion diagnostic test (Guardant360 CDx) to identify eligible patients.
Treatment Options for ESR1-Mutated Cancer
In January 2023, the FDA approved elacestrant (brand name Orserdu) specifically for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed on at least one prior line of endocrine therapy, including a CDK4/6 inhibitor. This was the first drug approved with ESR1 mutation status as part of its indication.
Elacestrant works as a selective estrogen receptor degrader, meaning it binds to the estrogen receptor and marks it for destruction rather than simply blocking it. In the clinical trial that led to its approval, patients with ESR1 mutations who received elacestrant had a median progression-free survival of 3.8 months compared to 1.9 months on standard-of-care endocrine therapy. At six months, 41% of elacestrant-treated patients had not progressed, versus 19% on standard therapy. The hazard ratio of 0.55 indicates a 45% reduction in the risk of disease progression or death for the ESR1-mutated group.
For patients with a detected ESR1 mutation after prior CDK4/6 inhibitor treatment, current guidelines from the American Society of Clinical Oncology list elacestrant as an option alongside other endocrine therapies used alone or combined with targeted agents. If the tumor also carries a PIK3CA mutation, alpelisib may be added. Everolimus is another combination option, though its benefit appears to depend on which specific ESR1 mutation is present. There are currently no data supporting the use of elacestrant in combination with targeted agents, so it is used as a single agent.